Our lead compound MASL specifically targets podoplanin (PDPN) to disrupt tumor cell communication pathways to inhibit tumor growth and spread, and trigger targeted tumor cell destruction

• New chemical entity bioactive lectin isolated from maackia amurensus seeds
• Broad anti-tumor potential validated in preclinical studies conducted with the NCI
• Animal studies show tumor inhibition with no adverse effects
• Potential for use as a monotherapy or as neoadjuvant therapy to standard of care
• Patients can be identified via standard protein and nucleic acid assays for early intervention and potentially prevention